Myelodysplasia with isolated trisomy 15: A 15-Year follow-up without specific therapy

American Journal of the Medical Sciences

Volumn 331, Issue 3, 2006, Pages 157-158

  Natelson, Ethan A ^a  

^a St Joseph's Medical Center Houston   (United States)

Author keywords

IPSS; Macrocytosis; Myelodysplasia; Pancytopenia; Trisomy 15

Indexed keywords

PESTICIDE;

ADULT; ARTICLE; CASE REPORT; CHROMOSOME ABERRATION; DISEASE COURSE; EXPOSURE; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; MEGALOCYTOSIS; MYELODYSPLASIA; PANCYTOPENIA; TRISOMY; TRISOMY 15;

ADULT; BLOOD CELL COUNT; CHROMOSOMES, HUMAN, PAIR 15; ENVIRONMENTAL EXPOSURE; FEMALE; HOUSING; HUMANS; MYELODYSPLASTIC SYNDROMES; PANCYTOPENIA; PESTICIDES; TRISOMY;

EID: 33645105649     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200603000-00009     Document Type: Article

References (10)

1. Cassola M, Malcovati L. Myelodysplastic syndromes - coping with ineffective hematopoiesis. N Engl J Med 2005;352:536-8.
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2097-8.
3. Maes B, Meeus P, Michaux L, et al. Application of the international prognostic scoring system for myelodysplastic syndromes. Ann Oncol 1999;10:825-9.
4. Batanian JR, Slovak ML, Mohamed A, et al. Trisomy 15 is frequently observed as a minor clone in patients with anemia/MDS/NHL and as a major clone in patients with AML. Cancer Genet Cytogenet 2000;121:186-9.
5. Smith SR, Rowe D. Trisomy 15 in hematological malignancies: six cases and review of the literature. Cancer Genet Cytogenet 1996;89:27-30.
6. Baumgartner BJ, Shurafa M, Terebelo H, et al. Trisomy 15, sex chromosome loss, and hematological malignancy. Cancer Genet Cytogenet 2000;117:132-5.
7. Morel F, Le Bris M-J, Herry A, et al. Trisomy 15 as the sole abnormality in myelodysplastic syndromes: case report and review of the literature. Leuk Lymphoma 2003;44:549-51.
8. Cutter CS, Lee SJ, Greenberg P, et al. A decision analysis of allogenic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low risk myelodysplasia is associated with improved outcome. Blood 2004;104:579-85.
9. Ho AYL, Pagliuca A, Kenyon M, et al. Reduced intensity allogenic hematopoietic stem cell transplantation for myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004;1616-23.
10. Gotlib J, Greenberg PL. Novel biospecific agents for the treatment of myelodysplastic syndromes. J Nat Comp Cancer Net 2003;1:473-80.